The U.S. Food and Drug Administration (FDA) has introduced Elsa 4.0, an upgraded version of its internal artificial intelligence (AI) tool designed to assist staff across the agency, including scientific reviewers and investigators. Concurrently, the agency consolidated more than 40 separate application and submission data sources into a unified platform named HALO (Harmonized AI & Lifecycle Operations for Data).
This consolidation and the integration of Elsa with HALO allow FDA staff to query data and build workflows directly without manually uploading documents for each interaction. The integration is intended to facilitate a deeper deployment of AI capabilities within FDA operations.
AI Enhancements in FDA Operations
Elsa 4.0 offers new features such as custom agents, document generation, quantitative data analysis with visualization tools, web searches through a secure access feature, voice-to-text dictation, optical character recognition (OCR) for scanned documents, enhanced chat flexibility, and optimized search functions for extensive document repositories.
The AI tool is hosted within a secure FedRAMP High certified Google Cloud Platform environment, ensuring data privacy by not training on user input or regulated industry data. While Elsa can access updated secure web data for responses, it is intentionally not connected to the public internet. Human experts verify all AI inputs, analyses, and outputs, maintaining oversight of the technology’s application within the agency.
Consolidation of Data Sources into HALO
Prior to this update, FDA staff had to manually bring data into Elsa. With the HALO platform now serving as a centralized repository, Elsa operates directly atop FDA data, streamlining access and analysis. According to Jeremy Walsh, the FDA’s Chief AI Officer, integrating AI into daily workflows is a critical priority to accelerate regulatory science advancements and expedite the delivery of new cures and treatments.
Why it matters
These developments position the FDA as a leader in applying AI to regulatory science and agency workflows, reducing administrative burdens on staff so they can concentrate more on scientific review and decision-making. The upgrades are expected to improve efficiency and potentially speed the evaluation and approval process for medical products, benefiting public health.
Background
The FDA’s Elsa AI tool was initially launched as Elsa 1.0 in June 2025, ahead of schedule and under budget. Since then, the agency’s Office of Digital Transformation has continuously enhanced the tool’s capabilities based on user feedback, extending its applications to streamline complex review and operational processes.
Sources
This article is based on reporting and publicly available information from the following source:
Read more Health & Public Health stories on Goka World News.